NO980251L - Behandling av konsentrasjonssvikt/hyperaktivitetsforstyrrelse - Google Patents

Behandling av konsentrasjonssvikt/hyperaktivitetsforstyrrelse

Info

Publication number
NO980251L
NO980251L NO980251A NO980251A NO980251L NO 980251 L NO980251 L NO 980251L NO 980251 A NO980251 A NO 980251A NO 980251 A NO980251 A NO 980251A NO 980251 L NO980251 L NO 980251L
Authority
NO
Norway
Prior art keywords
treatment
hyperactivity disorder
concentration failure
failure
concentration
Prior art date
Application number
NO980251A
Other languages
English (en)
Other versions
NO980251D0 (no
Inventor
John H Heiligenstein
Bennett Coleman Laguzza
Steven M Paul
Gary D Tollefson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9525909.9A external-priority patent/GB9525909D0/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO980251D0 publication Critical patent/NO980251D0/no
Publication of NO980251L publication Critical patent/NO980251L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En gruppe propanaminer, norpinfrinopptaksinhibitorer, blir benyttet for å behandle kon- sentrasjonssvikt/hyperaktivitetsforstyrrelse.
NO980251A 1995-07-24 1998-01-20 Behandling av konsentrasjonssvikt/hyperaktivitetsforstyrrelse NO980251L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US137395P 1995-07-24 1995-07-24
US634995P 1995-11-08 1995-11-08
GBGB9525909.9A GB9525909D0 (en) 1995-12-19 1995-12-19 Treatment of attention-defecit/hyperactivity disorder
PCT/US1996/012047 WO1997003665A1 (en) 1995-07-24 1996-07-18 Treatment of attention-deficit/hyperactivity disorder

Publications (2)

Publication Number Publication Date
NO980251D0 NO980251D0 (no) 1998-01-20
NO980251L true NO980251L (no) 1998-01-20

Family

ID=27268037

Family Applications (1)

Application Number Title Priority Date Filing Date
NO980251A NO980251L (no) 1995-07-24 1998-01-20 Behandling av konsentrasjonssvikt/hyperaktivitetsforstyrrelse

Country Status (14)

Country Link
EP (1) EP0756869A3 (no)
JP (1) JPH11510143A (no)
KR (1) KR19990035817A (no)
CN (1) CN1195287A (no)
AU (1) AU709704B2 (no)
CA (1) CA2227410A1 (no)
CZ (1) CZ16798A3 (no)
EA (1) EA000856B1 (no)
IL (1) IL122984A0 (no)
MX (1) MX9800589A (no)
NO (1) NO980251L (no)
NZ (1) NZ313076A (no)
WO (1) WO1997003665A1 (no)
YU (1) YU43996A (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA57107C2 (uk) * 1997-09-23 2003-06-16 Елі Ліллі Енд Компані Спосіб лікування розладу поведінки
UA56257C2 (uk) * 1997-09-23 2003-05-15 Елі Ліллі Енд Компані Спосіб лікування неадекватної визивної поведінки
AU9214498A (en) * 1997-09-23 1999-04-12 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
IL138855A0 (en) * 1998-04-09 2001-10-31 Upjohn Co New treatments for nervous disorders
US6586427B2 (en) 1998-04-09 2003-07-01 Pharmacia & Upjohn Company Treatments for nervous disorders
GB0219687D0 (en) 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
WO2004017977A2 (en) 2002-08-23 2004-03-04 Eli Lilly And Company 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
WO2004103356A2 (en) * 2003-05-15 2004-12-02 Eli Lilly And Company Treatment of emotional dysregulation
US20070032554A1 (en) * 2003-08-27 2007-02-08 Elililly And Company A Corporation Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
CN104684555A (zh) 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
HRP20221106T1 (hr) 2015-03-06 2022-11-25 Auspex Pharmaceuticals, Inc. Postupci liječenja abnormalnih nevoljnih poremećaja pokreta
US10188758B2 (en) * 2015-03-20 2019-01-29 Intra-Cellular Therapies, Inc. Organic compounds
JP2020029447A (ja) * 2018-06-25 2020-02-27 大原薬品工業株式会社 腸溶性高分子及び抗付着剤を含有する顆粒

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
DK0537915T3 (da) * 1991-09-27 1995-11-27 Lilly Co Eli N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylaminer som inhibitorer for epinephrin
ES2077358T3 (es) * 1992-10-08 1995-11-16 Lilly Co Eli N-alquil-3-fenil-3-(2-alquiltiofenoxi)propilaminas.
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
US5696168A (en) * 1995-07-24 1997-12-09 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder

Also Published As

Publication number Publication date
CZ16798A3 (cs) 1998-11-11
EP0756869A2 (en) 1997-02-05
IL122984A0 (en) 1998-08-16
AU6506196A (en) 1997-02-18
YU43996A (sh) 1999-06-15
EP0756869A3 (en) 1999-06-16
EA199800152A1 (ru) 1998-08-27
WO1997003665A1 (en) 1997-02-06
CA2227410A1 (en) 1997-02-06
MX9800589A (es) 1998-04-30
JPH11510143A (ja) 1999-09-07
NZ313076A (en) 1999-11-29
NO980251D0 (no) 1998-01-20
CN1195287A (zh) 1998-10-07
AU709704B2 (en) 1999-09-02
EA000856B1 (ru) 2000-06-26
KR19990035817A (ko) 1999-05-25

Similar Documents

Publication Publication Date Title
NO980251L (no) Behandling av konsentrasjonssvikt/hyperaktivitetsforstyrrelse
ATE234092T1 (de) 2-alkylpyrrolidine
NO991225D0 (no) Terapi for <alfa>-galaktosidase A mangel
NO954281L (no) Vannrensesystem
AU5624699A (en) Use of 5ht-6 antagonists
MX9606401A (es) Compuesto de indolinona para el tratamiento de enfermedades.
BG102644A (bg) Подобрени концентрирани инжекционни и инфузионниразтвори за интравазално прилагане
NO986100D0 (no) Androgene reseptormodulerende forbindelser og fremgangsmÕter
DK0768885T3 (da) Fremgangsmåde til inhibering af cancermetastase ved oral administration af oplöselig modificeret citruspectin
PL353750A1 (en) Dosages for treatment with anti-erbb2 antibodies
BR9808491A (pt) Compostos calcilìticos
EP0909561A3 (en) Use of reboxetine for the treatment of attention-deficit/hyperactivity disorder
DE69608804D1 (de) Di- und trivalente kleine moleküle als selektininhibitoren
TR200102864T2 (tr) N”rolojik ya da n”ropsikiyatrik bozukluklarìn tedavisi i‡in y”ntem
EA199800867A1 (ru) Соединения тетрагидробетакарболина
DE59510131D1 (de) Imidazopyridin-azolidinone
DK1143917T3 (da) Antikonvulsive derivater egnet til behandling af posttraumatisk stresssygdom
NO990450D0 (no) Behandling av sinnslidelser
TR200003203T2 (tr) Karboksaldehitin saflaştırılması
NO972607L (no) Sekvestreringsmidler
ATE40116T1 (de) 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva.
NO20005833D0 (no) Humaniserte antistoffer som gjenkjenner verotoksin II og cellelinje som produserer det samme
ATE222103T1 (de) Inklusionskomplexe in waessriger loesung
GR930100340A (el) Μέ?οδος για την καταπολέμηση εντόμων.
TR200000176T2 (tr) Propilen oksidin saflaştırılması.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application